Market Overview

Enanta Announces Data from Phase 2b Study for ABT-450 for Hepatitis C


Enanta Pharmaceuticals (NASDAQ: ENTA) announced today that new
Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor
identified in its ongoing collaboration with AbbVie, as well as new
preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546,
will be presented at the International Liver Congress, (ILC), which is
the 48th Annual Meeting of the European Association for the
Study of the Liver (EASL) taking place in Amsterdam April 24-28, 2013.

Results from "Aviator," AbbVie's Phase 2b clinical trial of ABT-450
combined with two of AbbVie's proprietary investigational direct-acting
antivirals (DAAs), for the treatment of hepatitis C

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ENTA)

View Comments and Join the Discussion!

Nidec to Make Nidec Copal, Nidec Tosok, Nidec Seimitsu Wholly Owned Subsidiaries

National Technical Systems Awarded $1.6M Contract from Sandia National Laboratories